Stephen P. Robertson - Feb 28, 2025 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Signature
/s/ Stephen P. Robertson
Stock symbol
AUPH
Transactions as of
Feb 28, 2025
Transactions value $
-$975,223
Form type
4
Date filed
3/4/2025, 08:57 PM
Previous filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Award $0 +84.1K +18.89% $0.00 529K Feb 28, 2025 Direct F1, F2
transaction AUPH Common Stock Award $0 +102K +19.35% $0.00 632K Mar 3, 2025 Direct F3
transaction AUPH Common Stock Sale -$519K -64.9K -10.27% $8.00 567K Mar 3, 2025 Direct F4, F5
transaction AUPH Common Stock Sale -$456K -57.6K -10.16% $7.92 509K Mar 4, 2025 Direct F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Employee Stock Option (right to buy) Award $0 +128K $0.00 128K Feb 28, 2025 Common Stock 128K $7.55 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2 Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 513 common shares were acquired on May 31, 2024 and 506 common shares were acquired on November 29, 2024.
F3 Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025.
F4 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award.
F5 The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants.
F7 The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8 One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.